Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS r...

Full description

Bibliographic Details
Main Authors: Wenqi Zhang, Chen Huang, Ruixia Liu, Huichao Zhang, Weijing Li, Shaoning Yin, Lianjing Wang, Wei Liu, Lihong Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
scnsl
CD19 CAR-T cell therapy
BTK inhibitor
PD-1 antibody
zanubrutinib
tislelizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.983934/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.983934/full

Similar Items